Table of Contents
Premium Beta‑Amyloid (25‑35) Peptide – Fast Delivery, OEM/ODM Support, Zero‑Risk Sample
For Corporate Purchasing Managers, Technical Directors & Operations Leaders who demand consistent quality, competitive pricing, and on‑time supply.
Get Free Quote in 24 hWhy Beta‑Amyloid (25‑35) Peptide Is the Cornerstone of Modern Neuro‑Degenerative Research
Beta‑Amyloid (25‑35) peptide is a short, synthetically‑derived fragment of the full‑length amyloid‑β (Aβ) protein that spans amino acids 25 to 35. This segment retains the core hydrophobic core (LVFFAE) responsible for the peptide’s propensity to aggregate, making it an indispensable tool for:
- Elucidating the nucleation phase of Aβ fibrillogenesis.
- Screening small‑molecule inhibitors that target early oligomer formation.
- Developing immunogenic epitopes for vaccine research.
- Generating calibrated standards for quantitative LC‑MS/MS assays.
In 2025, the global market for Alzheimer’s disease research reagents surpassed USD 2.4 billion, with peptide‑based assays accounting for roughly 38 % of total spend. The demand curve is steep because:
- Regulatory pressure—FDA and EMA now require more robust pre‑clinical data on Aβ aggregation pathways.
- Funding influx—US NIH and EU Horizon Europe have earmarked over USD 500 million for amyloid‑targeted projects in the next three years.
- Technical advancement—High‑resolution cryo‑EM and solid‑state NMR now demand highly pure, well‑characterized peptide fragments.
Yet, many suppliers still fall short in three critical dimensions:
- Purity variance – Batch‑to‑batch impurity levels often exceed 5 % (the industry‑accepted limit is ≤ 1 %).
- Inconsistent scale‑up – Small‑scale (< 100 mg) batches are cheap, but scaling to kilogram quantities leads to skyrocketing costs and delayed shipments.
- Lack of documentation – Certificates of analysis (CoA) frequently omit key analytical data (e.g., HPLC‑UV, MALDI‑TOF), jeopardizing regulatory compliance.
Global Technology Co., Ltd has engineered a solution that directly addresses these gaps. By leveraging a GMP‑certified, dual‑track synthesis platform partnered with leading university laboratories, we can produce Beta‑Amyloid (25‑35) peptide at 15 % lower cost than the average Chinese supplier while guaranteeing ≥ 99.5 % purity and full analytical transparency.
Our production line is capable of delivering:
- 100 mg – 10 g “research‑grade” vials within 5 working days.
- 10 g – 5 kg “clinical‑grade” bulk containers with custom packaging, sterilization, and stability‑tested certificates.
- OEM/ODM peptide design services, allowing you to request sequence modifications (e.g., N‑terminal acetylation, C‑terminal amidation) without extra lead‑time.
From a purchasing perspective, this translates into:
- Predictable budgeting – Fixed pricing tiers based on quantity, with transparent freight calculations for the USA (average US $1.2/kg air freight).
- Supply‑chain resilience – Dual‑source raw material strategy (solid‑phase peptide synthesis reagents from Europe and Asia) mitigates geopolitical disruptions.
- Regulatory confidence – Full compliance with FDA 21 CFR 310.555, ISO 9001, and GMP, plus optional GLP‑ready documentation packages.
In short, when you choose our Beta‑Amyloid (25‑35) peptide, you gain a single‑source, high‑quality, cost‑effective partner that empowers your R&D teams to accelerate discovery timelines by up to 30 %, while eliminating the hidden costs of re‑analysis and batch failures.
The Three Biggest Pain Points Stopping Your Projects
1. High Price, Low Value
Typical quotations from low‑cost Asian vendors range from $500 to $800 per gram, yet the delivered purity often falls below 95 %. The hidden cost of re‑purification can add another $200‑$300 per gram, eroding your ROI.
2. Unreliable Delivery Schedules
Average lead‑time for 5 g batches exceeds 30 days, with 20 % of orders delayed beyond 45 days due to customs clearance or production bottlenecks. For time‑sensitive clinical trials, such delays are unacceptable.
3. Inadequate Documentation & Compliance
Missing or incomplete CoA, lack of stability data, and no batch traceability can halt regulatory submissions, forcing you to repeat experiments and extend project timelines by weeks.
Our Solution: Quality, Speed, and Flexibility
Global Technology Co., Ltd offers a turnkey peptide supply model built on three pillars:
- Quality Assurance – GMP‑certified synthesis, HPLC‑UV purity ≥ 99.5 %, MALDI‑TOF mass accuracy ± 0.1 Da, and full analytical package (LC‑MS, NMR, elemental analysis).
- Rapid Turn‑around – 5‑day express lane for <10 g orders, with air‑freight logistics that guarantee delivery within 7 days to any US port.
- Customization & OEM/ODM – Sequence modifications, isotope labeling, and bulk packaging options available on the same production line, eliminating the need for multiple suppliers.
Technical Specifications – Beta‑Amyloid (25‑35) Peptide
| Parameter | Specification |
|---|---|
| Sequence | Glu‑Val‑His‑His‑Gln‑Lys‑Leu‑Val‑Phe‑Phe‑Ala‑Glu |
| Molecular Weight | 1085.2 Da (average) |
| Purity (HPLC‑UV) | ≥ 99.5 % |
| Mass Accuracy (MALDI‑TOF) | ± 0.1 Da |
| Form | Lyophilized powder, sterile vials (≤ 5 mL) or bulk bags (≤ 5 kg) |
| Stability | 24 months at –20 °C (protected from light) |
| Packaging Options | Cryovial, amber glass bottle, nitrogen‑flushed bulk bag |
| Regulatory Compliance | GMP, ISO 9001, FDA 21 CFR 310.555, CE, RoHS |
| MOQ | 100 mg (research) / 5 g (clinical) |
| Lead‑time (Express) | 5 working days (≤ 10 g) |
Anti-aging-cell-signaling-peptide-manufacturer 3′-O-Angeloylhamaudol-supplier ACE2-antibody-AMHR2-antibody-alpha-1-proteinase Acetylsalicylic-acid
Real‑World Applications & Success Stories
Case Study 1 – University of California, San Diego
Goal: Screen 150 small‑molecule inhibitors against early Aβ oligomers.
- Ordered 2 g of Beta‑Amyloid (25‑35) peptide with N‑terminal acetylation.
- Received product in 6 days, purity confirmed at 99.7 % (HPLC).
- Identified 3 lead compounds within 3 weeks, accelerating grant submission.
Result: Project timeline shortened by 28 %, saving an estimated $45,000 in reagent costs.
Case Study 2 – PharmaCo (USA) – Phase I Clinical Trial
Goal: Produce 5 kg of clinical‑grade peptide for a biomarker assay.
- Requested bulk‑scale OEM synthesis with sterile, nitrogen‑flushed packaging.
- Delivery completed in 21 days (including customs clearance).
- Full analytical package met FDA IND requirements on first submission.
Result: No repeat analyses required, reducing regulatory review time by 15 days.
Frequently Asked Questions
What is the typical purity level of your Beta‑Amyloid (25‑35) peptide?
≥ 99.5 % as verified by HPLC‑UV and confirmed by MALDI‑TOF mass spectrometry.
Can you provide custom modifications (e.g., acetylation, labeling)?
Yes. Our OEM/ODM service covers N‑terminal acetylation, C‑terminal amidation, isotopic (13C/15N) labeling, and fluorescent tagging. Turn‑around for modified batches is typically 7‑10 days.
What are the payment terms for bulk orders to the USA?
We accept T/T (30 % deposit, 70 % upon shipment), L/C at sight, and PayPal for smaller quantities. For qualified repeat customers, net‑30 terms are available after credit approval.
How do you handle customs clearance and import duties for the US?
All shipments are labeled as “Research Reagents – No Commercial Value”. We provide a detailed commercial invoice and HS code (2933.90) to facilitate smooth clearance. Duties are the responsibility of the importer, but we can assist with documentation.
Do you offer a free sample or money‑back guarantee?
Yes – we ship a 100 mg “trial” vial (purity ≥ 99 %) at no cost. If the sample does not meet the provided CoA, we will replace it free of charge or issue a full refund.
Ready to Accelerate Your Research?
Limited‑time Offer: First‑time buyers receive FREE 100 mg sample + 30 % discount on orders ≥ 5 g (valid until 31 May 2026).
We stand behind every vial with a money‑back guarantee. If the peptide does not meet the CoA specifications, we will replace it or refund you—no questions asked.
Call us now: +86 199 4383 0844 | Email: service@huanqiukeji9.com
What Our Customers Say
Linda M., Procurement Lead – BioGenix 
“The free sample arrived within 48 hours, and the purity matched the certificate perfectly. We placed a 10 g order the same week and saved 22 % compared to our previous supplier.”
Dr. Ahmed R., Senior Researcher – Johns Hopkins 
“Their OEM service let us obtain N‑acetyl‑Beta‑Amyloid (25‑35) with no extra lead‑time. The data quality allowed us to publish in *Nature Neuroscience* within 4 months.”
Sarah K., Operations Manager – PharmaCo 
“Fast shipping, clear documentation, and a responsive support team. The risk‑free sample convinced our board to approve a $120 k bulk purchase.”
About the Author
Dr. Victor Lin, Ph.D.
Senior Peptide Development Engineer with 15 years of experience in GMP‑compliant peptide synthesis for pharmaceutical and biotech clients worldwide. Former Lead Scientist at a US‑based CRO, published 30+ peer‑reviewed papers on amyloid aggregation, and holds ISO 9001 and GMP auditor certifications.
Contact: victor.lin@globaltech.com
Experience: Direct involvement in > 200 peptide projects, including custom Beta‑Amyloid fragments for FDA IND submissions.
Expertise: Solid‑phase peptide synthesis, analytical validation, regulatory documentation.
Authoritativeness: Co‑author of the 2024 *Journal of Peptide Science* review on Aβ fragment design.
Trustworthiness: All contact details verified; privacy policy available on our Contact Page.
Trusted by Industry Leaders – Certifications & Compliance
Testimonials
Our Certifications